{
    "relation": [
        [
            "Country",
            "Algeria",
            "Algeria",
            "Argentina",
            "Argentina",
            "Bangladesh",
            "Bangladesh",
            "Bhutan",
            "Bolivia",
            "Botswana",
            "Botswana",
            "Brazil",
            "Brazil",
            "Burundi",
            "Burundi",
            "Cambodia",
            "Cambodia",
            "Cameroon",
            "Cameroon",
            "Cape Verde",
            "Cape Verde",
            "Chile",
            "Chile",
            "Colombia",
            "Comoros",
            "Comoros",
            "C\u00f4te d Ivoire",
            "C\u00f4te d Ivoire",
            "Cuba",
            "Democratic Republic of Congo",
            "Democratic Republic of Congo",
            "Djibouti",
            "Dominican Republic",
            "Dominican Republic",
            "Ecuador",
            "El Salvador",
            "El Salvador",
            "Ethiopia",
            "Ethiopia",
            "Ghana",
            "Ghana",
            "Guatemala",
            "Guatemala",
            "Guinea",
            "Guinea",
            "Guyana",
            "Guyana",
            "Haiti",
            "Haiti",
            "India",
            "India",
            "Kenya",
            "Kenya",
            "Lesotho",
            "Lesotho",
            "Liberia",
            "Liberia",
            "Malawi",
            "Malawi",
            "Mauritania",
            "Mauritania",
            "Mexico",
            "Mexico",
            "Mozambique",
            "Myanmar",
            "Namibia",
            "Namibia",
            "Nepal",
            "Nepal",
            "Nicaragua",
            "Niger",
            "Nigeria",
            "Nigeria",
            "Pakistan",
            "Panama",
            "Panama",
            "Papua New Guinea",
            "Papua New Guinea",
            "Paraguay",
            "Peru",
            "Peru",
            "Philippines",
            "Russia",
            "Rwanda",
            "Rwanda",
            "Senegal",
            "Sierra Leone",
            "Sierra Leone",
            "South Africa",
            "South Africa",
            "Swaziland",
            "Swaziland",
            "Tanzania",
            "Tanzania",
            "Thailand",
            "Thailand",
            "Togo",
            "Uganda",
            "Uganda",
            "Ukraine",
            "Ukraine",
            "United States",
            "United States",
            "Uruguay",
            "Venezuela",
            "Venezuela",
            "Vietnam",
            "Vietnam",
            "Zambia",
            "Zambia",
            "Zimbabwe",
            "Zimbabwe"
        ],
        [
            "Clients/Year Issued",
            "Adults and adolescents 2010",
            "Infants and children 2010",
            "Adults and adolescents 2012",
            "Infants and children 2009",
            "Adults and adolescents 2011",
            "Infants and children 2011",
            "Infants and children 2008",
            "Adults and adolescents 2009",
            "Adults and adolescents 2012",
            "Infants and children 2012",
            "Adults and adolescents 2008",
            "Infants and children 2009",
            "Adults and adolescents 2010",
            "Infants and children 2010",
            "Adults and adolescents 2007",
            "Infants and children 2011",
            "Adults and adolescents No Date",
            "Infants and children No Date",
            "Adults and adolescents 2004",
            "Infants and children 2004",
            "Adults and adolescents 2010",
            "Infants and children 2010",
            "Adults and adolescents 2010",
            "Adults and adolescents 2007",
            "Infants and children 2007",
            "Adults and adolescents 2005",
            "Infants and children 2005",
            "Adults and adolescents 2009",
            "Adults and adolescents 2005",
            "Infants and children 2005",
            "Adults and adolescents 2008",
            "Adults and adolescents 2004",
            "Infants and children 2004",
            "Adults and adolescents 2007",
            "Adults and adolescents 2005",
            "Infants and children 2005",
            "Adults and adolescents 2008",
            "Infants and children 2008",
            "Adults and adolescents 2005",
            "Infants and children 2005",
            "Adults and adolescents 2012",
            "Infants and children 2012",
            "Adults and adolescents 2011",
            "Infants and children 2011",
            "Adults and adolescents 2011",
            "Infants and children 2011",
            "Adults and adolescents 2008",
            "Infants and children 2006",
            "Infants and children 2006",
            "Adults and adolescents 2007",
            "Adults and adolescents 2011",
            "Infants and children 2011",
            "Adults and adolescents 2007",
            "Infants and children 2007",
            "Adults and adolescents 2007",
            "Infants and children 2007",
            "Adults and adolescents 2011",
            "Infants and children 2011",
            "Adults and adolescents 2005",
            "Infants and children 2005",
            "Adults and adolescents 2012",
            "Infants and children 2012",
            "Adults and adolescents 2010",
            "Adults and adolescents 2011",
            "Adults and adolescents 2010",
            "Infants and children 2010",
            "Adults and adolescents 2009",
            "Infants and children 2009",
            "Adults and adolescents 2009",
            "Adults and adolescents 2009",
            "Adults and adolescents 2010",
            "Infants and children 2010",
            "Adults and adolescents 2005",
            "Adults and adolescents 2011",
            "Infants and children 2011",
            "Adults and adolescents 2009",
            "Infants and children 2009",
            "Adults and adolescents 2011",
            "Adults and adolescents 2004",
            "Infants and children 2009",
            "Adults and adolescents 2009",
            "Adults and adolescents 2007",
            "Adults and adolescents 2007",
            "Infants and children 2007",
            "Adults and adolescents No Date",
            "Adults and adolescents 2006",
            "Infants and children 2007",
            "Adults and adolescents 2010",
            "Infants and children 2010",
            "Infants and children 2006",
            "Adults and adolescents 2010",
            "Adults and adolescents 2009",
            "Infants and children 2009",
            "Adults and adolescents 2010",
            "Infants and children 2010",
            "Adults and adolescents 2010",
            "Adults and adolescents 2009",
            "Infants and children 2009",
            "Adults and adolescents 2006",
            "Infants and children 2007",
            "Adults and adolescents 2012",
            "Infants and children 2010",
            "Adults and adolescents 2006",
            "Adults and adolescents 2012",
            "Infants and children 2012",
            "Adults and adolescents 2009",
            "Infants and children 2009",
            "Adults and adolescents 2007",
            "Infants and children 2010",
            "Adults and adolescents 2010",
            "Infants and children 2010"
        ],
        [
            "Criteria For Starting ARV Treatment",
            "All patients with any of the following clinical symptoms: CDC category C; Recurrent oropharyngeal candidiasis; Herpes zoster; Weight loss > 10 kg; Prolonged fever; Prolonged diarrhea; or Visceral leishmaniasis All patients with: CD4 count < 500/mm3 In the following situations: Pregnant woman; Discordant couple; > 50 years; Coinfection with hepatitis B or hepatitis C; Cardiovascular risk factors; Symptomatic primary infection; or Viral load > 100,000 copies/mL",
            "All children < 2 years Immunological criteria: Children 25\u201359 months with CD4% < 25%; or Children > 5 years with CD4% < 20% or 25% with viral load > 100,000 copies/mL or Clinical criteria: Children of any age with CDC category B or C; or Children 24 months\u20135 years with CDC category B",
            "All patients with: CD4 count <350/mm3; or A history of AIDS-defining illness or clinically significant symptoms suggesting advanced disease Patients with the following conditions should also be initiated on ART: HIV-associated nephropathy; Hepatitis B coinfection when HBV treatment is indicated; Pregnancy; or Occupational exposure or high occupational risk Treatment recommended if CD4 count is > 350/mm3 and < 500/mm3.",
            "All children < 2 years Children 2\u20135 years with: AIDS-defining illness or clinically significant symptoms (CDC category B or C); or CD4% < 25% Children > 5 years with: AIDS-defining illness or clinically significant symptoms (CDC category B or C); or CD4 < 350/mm3 Treatment recommended if CD4 count is > 350/mm3 and < 500/mm3.",
            "All patients with: CD4 count \u2264 350/mm3; WHO clinical stage 3 or 4 irrespective of CD4 count; Active TB disease irrespective of CD4 count; or HBV infection requiring treatment irrespective of CD4 count",
            "All children < 2 years Children 25\u201359 months with: CD4 count \u2264 750/mm3 or CD4% \u2264 25%; or WHO pediatric clinical stage 3 or 4 irrespective of CD4 count Children > 5 years with: CD4 count \u2264 350/mm3; or WHO pediatric clinical stage 3 or 4 irrespective of CD4 count",
            "Children < 18 months of age with: CD4% < 25% (1500/mm3); TLC < 3400/mm3; or WHO pediatric clinical stage 3 or 4 Children 18 months to 5 years of age with: CD4% < 15% (500/mm3); TLC < 2300/mm3; or WHO pediatric clinical stage 3 or 4 Children > 5 years or age with: CD4% < 15% (200/mm3); TLC < 1200/mm3; or WHO pediatric clinical stage 3 or 4",
            "All patients with: WHO clinical stage 1, 2 or 3 with CD4 count < 500/mm3; or WHO clinical stage 4",
            "All patients with: CD4 count \u2264 350/mm3; or WHO clinical stage 3 or 4 * Adolescents who are Tanner stages 4 and 5 should be treated according to the adult ARV guidelines",
            "All infants and children < 24 months Children > 24 months with: CD4% \u2264 25% or CD4 count \u2264 750/mm3; or WHO pediatric clinical stage 3 or 4 * Adolescents who are Tanner stages 1, 2, and 3 should be treated according to the pediatric ARV guidelines with close clinical monitoring",
            "All patients with: CD4 count < 200/mm3; A history of AIDS-defining illness or clinically significant symptoms suggesting advanced disease; or CD4 count > 200/mm3 and < 350/mm3 with viral load >100,000 copies/mL",
            "All infants (< 12 months) Children 12\u201336 months with: CDC category B* or C; CD4% < 25% or CD4 count < 750/mm3; or Consider treatment if viral load > 100,000 copies/mL Children 36\u201360 months with: CDC category B* or C; CD4% < 20% or CD4 count < 500/mm3; or Consider treatment if viral load > 100,000 copies/mL Children > 5 years with: CDC category B* or C; CD4% < 15% or CD4 count < 350/mm3; or Consider treatment if viral load > 100,000 copies/mL * Except LIP, thrombocytopenia, pulmonary tuberculosis, persistent fever and single episode of pneumonia",
            "All patients with: CD4 count < 350/mm3 irrespective of WHO clinical stage; WHO clinical stage 3 or 4; TB; or Hepatitis B coinfection when HBV treatment is indicated",
            "All infants and children < 24 months Children \u2265 24 to < 59 months with: CD4% < 25% or CD4 count < 750 mm3; or WHO pediatric clinical stage 3 or 4 Children > 59 months with: CD4 count < 350 mm3; or WHO pediatric clinical stage 3 or 4",
            "Patients must fulfill psychosocial criteria to initiate ART. All patients with: CD4 count < 250/mm3; or WHO clinical stage 4 (defer ART if patient is coinfected with extra-pulmonary TB and CD4 count > 250/mm3)",
            "All infants and children < 24 months of age Children \u2265 24 to 59 months with: CD4 percent < 25% or CD4 count < 750/mm3; or WHO pediatric clinical stage 3 or 4 irrespective of CD4 Children \u2265 5 years with: CD4 count < 350/mm3",
            "All patients with: WHO clinical stage 4; WHO clinical stage 2 or 3 with TLC < 1200/mm3; or CD4 count < 200/mm3 irrespective of clinical stage",
            "",
            "All patients with: WHO clinical symptoms (major or minor clinical signs related to HIV infections); CD4 count < 200/mm3; Viral load > 30,000 RNA copies/mL (by bDNA test) or 55,000 RNA copies/mL (by PCR test); or Consider treatment if CD4 > 200/mm3 and < 350/mm3",
            "All children with: Symptoms associated with HIV infection (AIDS-defining conditions); Evidence of immunosuppression (CDC categories 2 or 3); or Viral load > 100,000 copies/mL",
            "All patients with: CDC category B with CD4 count < 350/mm3; CD4 count > 200/mm3 and < 350/mm3 with two consecutive measurements < 350/mm3, one month apart; CD4 count < 200/mm3, only one measurement necessary; or CDC category C OI",
            "All children with: Evidence of severe immunosuppression (WHO pediatric clinical stage 3); or Evidence of certain clinical manifestations of disease (CDC category B) and CD4% below age threshold or viral load above age threshold as follows: 0 to \u2264 3 months: CD4% < 30%; viral load > 1,000,000 copies/mL 3 to \u2264 6 months: CD4% < 25%; viral load > 1,000,000 copies/mL 6 to \u2264 12 months: CD4% < 20%; viral load > 1,000,000 copies/mL 1 to 3 years: CD4% < 20%; viral load > 300,000 copies/mL 3 to 5 years: CD4% < 15%; viral load > 250,000 copies/mL \u2265 5 years: CD4% < 15% or CD4 count < 200/mm3; viral load > 250,000 copies/mL",
            "All patients with: CDC category B or C; or CD4 count < 200/mm3 Consider treating patients with: CD4 count between 200 and 250/mm3; or CD4 count between 250 and 350/mm3 and a viral load > 100,000 copies/mL",
            "All patients with: WHO clinical stage 4; CD4 count < 200/mm3; or CD4 count between 200 and 350/mm3 according to clinical and laboratory criteria",
            "All patients with: WHO pediatric clinical stage 3 or 4; or WHO pediatric clinical stage 1 or 2 and CD4% < 25%",
            "All patients with: CD4 count < 200/mm3; CD4 count < 350/mm3 and CDC Category B; or WHO clinical stage 2, 3 or 4 or CDC Category C",
            "Children < 18 months with: WHO pediatric clinical stage 3 or CDC category C irrespective of CD4%; or WHO pediatric clinical stage 1 or 2 with CD4% < 20% Children > 18 months with: CD4% < 15%; or WHO pediatric clinical stage 3 or CDC category C",
            "All patients with CD4 count < 350/mm3 Patients with special conditions, including: Viral load > 55,000 copies/mL Co-morbidities such as Hepatitis B or C, cirrhosis of the liver, or cancer Age > 55 years",
            "All patients with: CD4 count < 200/mm3; WHO clinical stage 4; or CD4 count < 350/mm3 at WHO clinical stage 3",
            "Children < 18 months of age with: WHO pediatric clinical stage 3 irrespective of CD4%; or WHO pediatric clinical stage 1 or 2 with CD4% < 20% Children > 18 months of age with: WHO pediatric clinical stage 3 irrespective of CD4%; or WHO pediatric clinical stage 1 or 2 with CD4% < 15%",
            "All patients with: CD4 count < 350/mm3; WHO clinical stage 4; or WHO clinical stage 3 when CD4 testing is not available",
            "All patients with: CD4 count < 200/mm3 and WHO clinical stage 1, 2 or 3; WHO clinical stage 4; Rapid CD4 decline (>20/mm3/month) and viral load > 100,000 copies/mL; or WHO clinical stage 2 or 3 and TLC < 1200/mm3",
            "Children < 18 months of age with: WHO pediatric clinical stage 3; or WHO pediatric clinical stage 1 or 2 and CD4% < 20% Children > 18 months and < 13 years of age with: WHO pediatric clinical stage 3; or WHO pediatric clinical stage 1 or 2 and CD4 % < 15%",
            "All patients with: CD4 count < 200/mm3; AIDS-defining illness or CDC Category B or C symptoms; or CD4 count > 200/mm3 but < 350/mm3 with a viral load > 100,000 copies/mL",
            "Evaluate the following: Presence of symptoms associated with HIV Diagnostic confirmation with 2 ELISA tests and other confirmatory tests as required by diagnostic algorithm in use A low CD4 count according to international standards A high viral load according to international standards; and A psychosocial assessment approved by the institutional committee",
            "All children should get a psychosocial evaluation approved by the institutional committee. Infants (< 12 months of age) of infected mothers independent of immunological state and viral load, especially those with: Clinical evidence of HIV infection (CDC Category B or C) Clinical evidence of immunosuppression (WHO pediatric clinical stage 2 or 3); or Viral load > 300,000 copies/mL Children 1 to 3 years of age with: Clinical evidence of HIV infection (CDC Category B or C); Clinical evidence of immunosuppression (WHO pediatric clinical stage 2 or 3); Viral load > 100,000 copies/mL; or Drop in a Category based on a decrease in CD4 count or percent within a 3-6 month period Children 3 to 13 years of age with: Clinical evidence of HIV infection (CDC Category B or C); Clinical evidence of immunosuppression (WHO pediatric clinical stage 2 or 3); Viral load > 20,000 copies/mL; or Drop in a Category based on a decrease in CD4 count or percent within a 3-6 month period",
            "All patients with: CD4 count < 200/mm3; WHO clinical stage 4; or CD4 count < 350/mm3 at WHO clinical stage 3",
            "All infants (< 12 months) Children from 1\u20135 years with: WHO pediatric clinical stage 3 or 4; or WHO pediatric clinical stage 1 or 2 at CD4% < 20% Children > 5 years with: CD4% < 15%",
            "All patients with: CD4 count < 350/mm3; or WHO clinical stage 3 or 4 For pregnant women where CD4 count > 350/mm3, initiate ARV prophylaxis at 28 weeks for the purpose of PMTCT.",
            "Children < 18 months with: WHO pediatric clinical stage 3 or 4 irrespective of CD4%; or WHO pediatric clinical stage 2 with CD4% < 20% Children > 18 months with: WHO pediatric clinical stage 3 or 4 irrespective of CD4%; or CD4% < 15%",
            "All patients with: AIDS-defining illness; CD4 count \u2264 350/mm3; Coinfection with hepatitis B and other clinical conditions associated with HIV that compromise the life of the patient; \u2265 14 months gestation; TLC < 1200/mm3; or declining CD4 count > 30% compared to the previous count",
            "All infants (< 12 months) Children 1\u20135 years with: CDC category B or C ; CD4% < 25%; or Viral load > 100,000 copies/mL Children 6\u201312 years with: CDC category B or C; CD4 count < 350/mm3; or Viral load > 100,000 copies/mL",
            "All patients with: CD4 count < 350/mm3; or WHO stage 3 or 4 irrespective of CD4 count Treatment of patients with CD4 counts between 350 and 500/mm3 should be discussed with regard to: clinical course; viral load when available; and patient motivation",
            "Infants \u2264 11 months with: CD4% < 25% or CD4 count < 1500/mm3; or WHO pediatric clinical stage 3 or 4 irrespective of CD4 Children 12\u201335 months with: CD4% < 20% or CD4 count < 750/mm3; WHO pediatric clinical stage 4 irrespective of CD4; or WHO pediatric clinical stage 3 irrespective of CD4 count or TLC, but use CD4 as a guide for children with TB, LIP, OHL, or thrombocytopenia Children 36\u201359 months with: CD4% < 15% or CD4 count < 350/mm3; WHO pediatric clinical stage 4 irrespective of CD4; or WHO pediatric clinical stage 3 irrespective of CD4 count or TLC, but use CD4 as a guide for children with TB, LIP, OHL, or thrombocytopenia Children > 5 years with: CD4% < 15% or CD4 count < 200/mm3; WHO pediatric clinical stage 4 irrespective of CD4; or WHO pediatric clinical stage 3 irrespective of CD4 count or TLC, but use CD4 as a guide for children with TB, LIP, OHL, or thrombocytopenia",
            "All patients with: CD4 count < 350/mm3 irrespective of WHO or CDC staging; or WHO clinical stage 3 or 4 irrespective of CD4 count Consider starting treatment in patients with CD4 count 351\u2013500/mm3 if patient is highly motivated or there are other risk factors (e.g., hepatitis B, renal failure, cardiovascular disease).",
            "All children < 2 years Children 2\u20135 years with: WHO pediatric clinical stage 3 or 4; or CD4% < 25% or CD4 count < 750/mm3 Children > 5 years with: WHO pediatric clinical stage 3 or 4; or CD4% < 20% or CD4 count < 350/mm3 Can offer antiretroviral therapy to all children above initiation thresholds after conducting a thorough adherence assessment.",
            "All patients with: CD4 count < 200/mm3; or WHO clinical stage 3 or 4 Those with a CD4 count > 200/mm3 but < 350/mm3 may be considered for treatment.",
            "Infants \u2264 11 months with WHO pediatric clinical stage 3 or 4 irrespective of CD4% Children 12\u201335 months with: CD4% < 20% (CD4 count < 750/mm3); TLC \u2264 3000/mm3; WHO pediatric clinical stage 4; or TB, LIP, OHL, or thrombocytopenia Children 36\u201359 months with: CD4% < 15% (CD4 count < 350/mm3); TLC \u2264 2500/mm3; WHO pediatric clinical stage 4; or TB, LIP, OHL, or thrombocytopenia Children \u2265 5 years with: CD4% < 15% (CD4 count < 200/mm3); TLC \u2264 2000/mm3; WHO pediatric clinical stage 4; or TB, LIP, OHL, or thrombocytopenia",
            "Clinical Markers Infants < 12 months with: WHO pediatric clinical stage 3 or 4 Children > 12 months with: WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3, but use CD4 as a guide for children with TB, LIP, OHL, or thrombocytopenia Immunological Markers Infants < 11 months with: CD4 count < 1500/mm3 (25%) Children 12\u201335 months with: CD4 count < 7500/mm3 (20%) Children 36\u201359 months with: CD4 count < 350/mm3 (15%) Children > 5 years with: CD4 count < 200/mm3; or CD4 count < 350/mm3 at WHO pediatric clinical stage 3",
            "All patients with: CD4 count < 200/mm3; or WHO clinical stage 4 Those with a CD4 count > 200/mm3 but < 350/mm3 at WHO clinical stage 3 may be considered for treatment.",
            "All patients with: CD4 count \u2264 350/mm3; WHO clinical stage 3 or 4; TB disease; HIV/hepatitis B coinfection with evidence of active/chronic liver disease; or HIV-associated nephropathy",
            "All children \u2264 24 months Children 25\u201359 months with: WHO pediatric clinical stage 3 or 4; or CD4% < 25% or CD4 count < 1000/mm3 Children 5\u201312 years with: WHO pediatric clinical stage 3 or 4; or CD4% < 20% or CD4 count < 500/mm3",
            "All patients with: WHO clinical stage 3 or 4; or CD4 count < 350/mm3",
            "All infants < 12 months with: WHO pediatric clinical stage 3 or 4; or WHO pediatric clinical stage 1 or 2, but consult a specialist for assistance Children 12\u201335 months with: WHO pediatric clinical stage 3 or 4; or CD4% < 20% or CD4 count < 750/mm3 Children 36\u201359 months with: WHO pediatric clinical stage 3 or 4; or CD4% < 20% or CD4 count < 350/mm3 Children \u2265 5 years with: WHO pediatric clinical stage 3 or 4; or CD4% < 15% or CD4 count < 350/mm3 An infant or child who has been diagnosed using presumptive criteria can also be initiated on HAART.",
            "All patients with: CD4 count < 200/mm3; WHO clinical stage 4; WHO clinical stage 2 and CD4 count < 200/mm3 or TLC < 1200/mm3; or WHO clinical stage 3 and CD4 count < 350/mm3",
            "All infants and children with: WHO pediatric clinical stage 3 or 4 Infants < 11 months with: CD4% < 25% (CD4 count < 1500/mm3); or WHO pediatric clinical stage 2 and TLC < 4000/mm3 Children 12\u201335 months with: CD4% < 20% (CD4 count < 750/mm3); or WHO pediatric clinical stage 2 and TLC < 3000/mm3 Children 36\u201359 months with: CD4% < 15% (CD4 count < 350/mm3); or WHO pediatric clinical stage 2 and TLC < 2500/mm3 Children \u2265 5 years with: CD4% < 15% (CD4 count < 200/mm3); or WHO pediatric clinical stage 2 and TLC < 2000/mm3",
            "All patients with: CD4 count \u2264 350/mm3; WHO clinical stage 3 or 4; or Women who are pregnant or breastfeeding",
            "All infants and children < 24 months. Children \u2265 24 months to < 5 years with: WHO pediatric clinical stage 1 or 2 and CD4 \u2264 750/ mm3 or CD4% \u2264 25%; or WHO pediatric clinical stage 3 or 4 Children \u2265 5 years with: CD4 count \u2264 350/ mm3; or WHO pediatric clinical stage 3 or 4",
            "All patients with: WHO clinical stage 4 irrespective of CD4 count; WHO clinical stage 3 with a CD4 count < 350/mm3; WHO clinical stage 1 or 2 with a CD4 count < 200/mm3; or WHO clinical stage 2 or 3 with a TLC < 1200/mm3",
            "Children < 18 months with: WHO pediatric clinical stage 3 irrespective of CD4%; or WHO pediatric clinical stage 1 or 2 with a CD4% < 20% Children \u2265 18 months with: WHO pediatric clinical stage 3 irrespective of CD4%; or WHO pediatric clinical stage 1 or 2 with a CD4% < 15%",
            "All patients with: CD4 count < 350/mm3; AIDS-defining illness; Pregnancy; Chronic hepatitis B coinfection when HBV treatment is indicated; HIV-associated nephropathy; or Acute retroviral syndrome (primary infection)",
            "All infants < 12 months Children \u2265 1 to < 5 years with: CDC category C or B (other than single episode of severe bacterial infection or LIP; CD4% < 25%; or Viral load > 100,000 copies/mL Children > 5 years with: CDC category C or B (other than single episode of severe bacterial infection or LIP); CD4 count < 500/mm3; or Viral load > 100,000 copies/mL",
            "All patients with: WHO clinical stage 4; CD4 count \u2264 350/mm3 at WHO clinical stage 3 (treat if CD4 is unavailable); or CD4 count \u2264 250/mm3 at WHO clinical stage 1 or 2 (do not treat if CD4 is unavailable)",
            "All patients with: CD4 count \u2264 350/mm3 irrespective of WHO clinical stage; or WHO clinical stage 3 or 4 irrespective of CD4 count",
            "All patients with: WHO clinical stage 3 or 4 irrespective of CD4 count; or CD4 count \u2264 350/mm3",
            "All children < 24 months Children 24\u201359 months with: WHO pediatric clinical stage 3 or 4 irrespective of CD4%; or WHO pediatric clinical stage 1 or 2 with a CD4% \u2264 25% Children \u2265 5 years with: WHO pediatric clinical stage 3 or 4 irrespective of CD4 count; or WHO pediatric clinical stage 1 or 2 with a CD4 count \u2264 350/mm3",
            "All patients with: WHO clinical stage 1 or 2 with CD4 count < 350/mm3; or WHO clinical stage 3 or 4 irrespective of CD4 count",
            "All infants < 12 months Children 12\u201335 months with: CD4% < 20% or CD4 count < 750/mm3; TLC < 3000/mm3; WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 guided by CD4 in those with OHL, LIP, TB, or thrombocytopenia Children 36\u201359 months with: CD4% < 20% or CD4 count < 350/mm3; TLC < 2500/mm3; WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 guided by CD4 in those with OHL, LIP, TB, or thrombocytopenia Children > 5 years with: CD4% < 15% or CD4 count < 200/mm3; TLC < 2000/mm3; WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 guided by CD4 in those with OHL, LIP, TB, or thrombocytopenia",
            "All patients with: CD4 count < 350/mm3; AIDS-defining illness or symptoms of advanced disease (CDC category B or C), hepatitis B, or HIV-associated nephropathy; or CD4 count > 350/mm3 and viral load > 100,000 copies/mL",
            "All patients with: WHO clinical stage 4 irrespective of CD4 count; WHO clinical stage 1, 2, or 3 and CD4 count < 350/mm3; or WHO clinical stage 3 if CD4 count is not available",
            "All patients with: CD4 count < 350/mm3 irrespective of clinical symptoms; or WHO clinical stage 3 or 4 Consider treatment in patients with CD4 count > 350/mm3 if: Patient has HIV-associated nephropathy; or Patient is in a discordant relationship",
            "All children < 24 months Children 24\u201359 months with: CD4% \u2264 25% or CD4 count \u2264 750 cells/mm3; or WHO pediatric clinical stage 3 or 4 Children \u2265 5 years with: CD4 < 350 cells/mm3; or WHO pediatric clinical stage 3 or 4",
            "If CD4 testing is available: CD4 count < 200/mm3; WHO clinical stage 4; or Consider treatment when CD4 count < 350/mm3 and WHO clinical stage 3 If CD4 testing is not available: TLC < 1200/mm3 at WHO clinical stage 2; or WHO clinical stage 3 or 4",
            "All patients with: AIDS-defining illness or symptoms of advanced disease; CD4 count \u2264 350/mm3; or CD4 count between 350 and 500/mm3 and viral load \u2265 100,000 copies/mL",
            "All children < 2 years Children 2 to < 5 years with: AIDS-defining illness or symptoms of advanced disease; or CD4% \u2264 25% or CD4 count \u2264 750/mm3 irrespective of symptoms Consider treatment in children 2 to < 5 years with: Mild symptoms or asymptomatic; CD4% \u2265 25%; and Viral load \u2265 100,000 copies/mL Children \u2265 5 years with: AIDS-defining illness or symptoms of advanced disease; or CD4 count < 350/mm3 Consider treatment in children \u2265 5 years with: Mild symptoms or asymptomatic; CD4 count \u2265 350/mm3; and Viral load \u2265 100,000 copies/mL",
            "All patients with: CD4 count < 350/mm3; WHO clinical stage 3 or 4 irrespective of CD4; or WHO clinical stage 2 with TLC < 1200/mm3",
            "All infants < 12 months Children 12\u201335 months with: CD4% < 20% or CD4 count < 750/mm3; TLC < 3000/mm3; WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 guided by CD4 in those with OHL, LIP, TB, or thrombocytopenia Children 36\u201359 months with: CD4% < 20% or CD4 count < 350/mm3; TLC < 2500/mm3; WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 guided by CD4 in those with OHL, LIP, TB, or thrombocytopenia Children \u2265 5 years with: CD4% < 15% or CD4 count < 350/mm3; TLC < 2000/mm3; WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 guided by CD4 in those with OHL, LIP, TB, or thrombocytopenia",
            "All patients with: AIDS-defining illness; CD4 count \u2264 350/mm3; or TLC < 1200/mm3 Consider treatment in patients with CD4 count > 350/mm3 and: > 55 years; Drop in CD4 count of > 120/mm3 per year; Certain comorbidities exist; or Viral load >100,000 copies/mL ART should be initiated independent of CD4 count in cases of: Pregnancy; HIV-associated nephropathy; Hepatitis B coinfection where Hepatitis B is active and/or treatment is indicated; Active Hepatitis C coinfection; or High cardiovascular risk",
            "All patients with: CDC category C; Recurrent oral candidiasis; HIV-related symptoms (fever of unknown origin, involuntary weight loss, diarrhea > 1 month); CD4 count < 200/mm3; or Viral load > 55,000 copies/mL",
            "Children < 12 months with: CDC category C irrespective of immunological category and viral load; or CDC category N, A, or B with moderate or severe immunosuppression (according to WHO) (CD4% < 35%) Consider treatment in children < 12 months with: CDC category A or B without immunosuppression, irrespective of viral load Children > 12 months with: CDC category C with severe immunosuppression irrespective of viral load and clinical category; or Moderate immunosuppression (according to WHO) and a viral load > 100,000 copies/mL, irrespective of clinical category Consider treatment in children > 12 months with: CDC category N, A, or B with moderate immunosuppression and/or viral load < 100,000 copies/mL For adolescents > Tanner stage 3 and/or > 40 kg, treat as adults.",
            "All patients with: CD4 count < 200/mm3; or WHO clinical stage 3 and 4 Those with a CD4 count > 200/mm3 but < 350/mm3 at WHO clinical stage 3 may be considered for treatment.",
            "All patients with: CD4 count < 200/mm3 The Ministry of Health of the Russian Federation also recommends treatment if: CD4 count is between 200 and 350/mm3; and Viral load > 100,000 copies/mL",
            "All patients with: CD4 count < 350/mm3; or WHO clinical stage 4",
            "Infants < 11 months with: CD4 count < 1500/mm3 (25%) Children 12\u201335 months with: CD4 count < 7500/mm3 (20%) Children 36\u201359 months with: CD4 count < 350/mm3 (15%) Children > 5 years with: CD4 count < 350/mm3 at WHO pediatric clinical stage 1, 2 or 3; or WHO pediatric clinical stage 4",
            "All patients with: CD4 count \u2264 200/mm3; CDC category B and CD4 count \u2264 350/mm3; or CDC category C",
            "All patients with: A history of AIDS-defining illness; CD4 count < 350/mm3; WHO clinical stage 3 or 4; or TLC < 1000\u20132000/mm3 (if CD4 count is unavailable) and WHO clinical stage 2",
            "All children with: Recurrent hospitalizations (> 2 admissions/year) or prolonged hospitalization (> 4 weeks) for HIV-related disease; WHO pediatric clinical stage 4; WHO pediatric clinical stage 3 irrespective of CD4 count, but use CD4 as a guide for children > 12 months with TB, LIP, OHL, or thrombocytopenia; or WHO pediatric clinical stage 1 or 2 and CD4 or TLC value at or below the threshold If virological testing is not available to confirm HIV infection, HIV antibody\u2013positive infants and children < 18 months who have clinically diagnosed presumed severe HIV disease should be considered for ART.",
            "All patients with: CD4 count \u2264 200/mm3; WHO clinical stage 4; CD4 count \u2264 350/mm3 and coinfected with TB; or MDR or XDR TB",
            "All infants (< 12 months) Children 12 months to 5 years with: CD4% \u2264 25% (750/mm3); or WHO pediatric clinical stage 3 or 4 Children > 5 years with: CD4 count < 350/mm3; or WHO pediatric clinical stage 3 or 4",
            "All children with: WHO pediatric clinical stage 3 or 4 irrespective of CD4 count or percentage; or WHO pediatric clinical stage 1 or 2, if the CD4 immunological stage is \u201csevere\u201d",
            "All patients with: CD4 count < 350/mm3; WHO clinical stage 3 or 4; Any form of TB, especially drug-resistant TB; Hepatitis B coinfection; or HIV-associated nephropathy",
            "All patients with: WHO clinical stage 4 irrespective of CD4 count; CD4 count \u2264 200/mm3 irrespective of WHO clinical stage; or CD4 count between 200 and 350/mm3 at WHO clinical stage 3",
            "All infants < 12 months Children 12\u201318 months with: WHO pediatric clinical stage 3 or 4 irrespective of CD4%; or WHO pediatric clinical stage 1 or 2 with CD4% < 20% or CD4 count < 750/mm3 Children > 18 months with: WHO pediatric clinical stage 3 or 4 irrespective of CD4%; or WHO pediatric clinical stage 1 or 2 with: CD4% < 20% or CD4 count < 750/mm3 for children 19\u201335 months; CD4% < 20% or CD4 count < 350/mm3 for children 36\u201359 months; or CD4% < 15% or CD4 count < 200/mm3 for children \u2265 5 years",
            "All patients with: CD4 count \u2264 350/mm3; AIDS-defining illness; HIV-related symptoms; or Pregnant women* * But discontinue after delivery for those women with a pretreatment CD4 count of \u2265 350/mm3",
            "All infants (< 12 months) Children 1\u20135 years with: CD4% < 25%; WHO pediatric clinical stage 3 or 4; or CDC category B or C Children > 5 years with: CD4 count < 350/mm3; WHO pediatric clinical stage 3 or 4; or CDC category B or C",
            "All patients with: CD4 count \u2264 350/mm3; or WHO clinical stage 3 or 4 irrespective of CD4 count",
            "All patients with: CD4 count \u2264 250/mm3; WHO clinical stage 4; or CD4 count > 250 but \u2264 350/mm3 in those: Coinfected with TB; WHO clinical stage 3; or Pregnant women",
            "All infants (< 12 months) Children 12\u201335 months with CD4% \u2264 20% (CD4 count \u2264 750/mm3) Children 36\u201359 months with CD4% \u2264 20% (CD4 count \u2264 350/mm3) Children \u2265 5 years with CD4% \u2264 15% (CD4 count \u2264 250/mm3)",
            "All patients with: CD4 count < 200/mm3; WHO clinical stage 4; or CD4 count < 350/mm3 and WHO clinical stage 3 Consider treatment if CD4 count > 200/mm3 and < 350/mm3 and WHO clinical stage 1 or 2.",
            "Infants \u2264 11 months: CD4% \u2264 25% (CD4 count \u2264 1500/mm3); or WHO pediatric clinical stage 3 or 4 Children 12\u201335 months: CD4% \u2264 20% (750/mm3); WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 with specific OIs* Children 36\u201359 months: CD4% \u2264 15% (350/mm3); WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 with specific OIs* Children \u2265 5 years: CD4% \u2264 15% (200/mm3); WHO pediatric clinical stage 4; or WHO pediatric clinical stage 3 with specific OIs* * TB, LIP, OHL, or thrombocytopenia",
            "All patients with: CD4 count \u2264 500/mm3; Pregnancy History of an AIDS-defining illness; HIV-associated nephropathy; or Hepatitis B co-infection",
            "All infants (< 12 months) Children \u2265 1 with: AIDS or significant symptoms (CDC category C or most category B conditions); or Age-related CD4 threshold (CD4% \u2264 25% for ages 1 to < 5 years and CD4 count < 350/mm3 for \u2265 5 years) and viral load \u2265 100,000 copies/mL",
            "All patients with: Acute symptomatic infection; HIV-related symptoms; or CD4 < 250/mm3 irrespective of symptoms and viral load",
            "All patients with: AIDS-defining illness; CD4 count < 350/mm3 or CD4% < 15%; HIV-related nephropathy; or Coinfection with HBV or HCV Treat patients with special considerations such as: Pregnancy; Any neoplastic disease; Serodiscordant stable partnerships; or > 55 years of age",
            "All infants < 12 months Children 1 to < 5 years with: Any CDC category B or C symptoms\u2014except one episode of a severe bacterial infection\u2014irrespective of CD4 levels; or CD4% < 25% Consider treatment in asymptomatic children 1 to < 5 years with CD4% \u2265 25% and viral load \u2265 100,000 copies/mL. Children > 5 years with: Any CDC category B or C symptoms \u2014except one episode of a severe bacterial infection\u2014 irrespective of CD4 levels; or CD4 count < 350/mm3 Consider treatment in asymptomatic children > 5 years with CD4 count \u2265 350/mm3 and viral load \u2265 100,000 copies/mL.",
            "All patients with: WHO clinical stage 4 irrespective of CD4 count; WHO clinical stage 3 and CD4 count < 350/mm3; WHO clinical stage 1 or 2 and CD4 count < 250/mm3; or If CD4 count is not available, start ART in patients at WHO clinical stages 3 or 4",
            "All infants < 12 months Children > 12 months with: WHO pediatric clinical stage 3 or 4 irrespective of CD4 count; TB, LIP, OHL, or thrombocytopenia (begin ART if CD4 represents \u201csevere immunodeficiency\u201d* by age once the OI is treated); WHO pediatric clinical stage 2 and CD4 count (or TLC) below the level of \u201csevere immunodeficiency\u201d* by age; or WHO pediatric clinical stage 1 and CD4 count below the level of \u201csevere immunodeficiency\u201d* by age * See pg. 97 of guidelines for pediatric immunological staging.",
            "All patients with: CD4 count < 200/mm3; WHO clinical stage 4; or CD4 count < 350/mm3 at WHO clinical stage 3",
            "All children < 2 years Children \u2265 2 and < 5 years with: CD4% \u2264 25% or CD4 \u2264 750 cells/mm3; or WHO pediatric clinical stage 3 or 4 Children \u2265 5 years with: CD4 \u2264 350 cells/mm3; or WHO pediatric clinical stage 3 or 4",
            "All patients with: WHO clinical stage 3 or 4; CD4 count < 350/mm3; or Active TB",
            "All infants < 12 months Children \u2265 1 and < 5 years with: WHO pediatric clinical stage 3 or 4; or CD4% \u2264 25% or CD4 count < 750/mm3 Children \u2265 5 years with: WHO pediatric clinical stage 3 or 4; or CD4 count < 350/mm3"
        ],
        [
            "First Line Regimen",
            "AZT + 3TC + EFV",
            "Infants: AZT + 3TC + PI/r or AZT + 3TC + NVP if the mother did not receive NVP during pregnancy",
            "ABC + 3TC + EFV or NVP; TDF + FTC or 3TC + EFV or NVP; or AZT + 3TC + EFV or NVP Can replace EFV or NVP with ATV/r or LPV/r or FPV/r or SQV/r",
            "Children < 3 years: AZT + 3TC or FTC + NVP or ABC + 3TC or FTC + NVP Children > 3 years: AZT + 3TC or FTC + EFV; ABC + 3TC or FTC + EFV or TDF (only in children > 12 years at Tanner stage 4 or 5) + 3TC or FTC + EFV",
            "AZT + 3TC + EFV or NVP; or TDF + 3TC + EFV or NVP (use for HIV/HBV coinfection)",
            "Infants group 1 (not exposed to ARVs or unknown exposure): Preferred: AZT + 3TC + NVP Alternative: ABC + 3TC + NVP Infants group 2 (exposed to maternal or infant NVP or other NNRTIs used for maternal treatment or PMTCT): Preferred: AZT + 3TC + LPV/r Alternative: AZT + 3TC + NVP (only when PIs are not available or not feasible) Children 12\u201324 months group 1 (exposed to maternal or infant NVP or other NNRTIs used for maternal treatment or PMTCT): Preferred: AZT + 3TC + LPV/r Alternative: AZT + 3TC + NVP Children 12\u201324 months group 2 (not exposed to NNRTIs): Preferred: AZT + 3TC + NVP Alternative: ABC + 3TC + NVP 3 years and older: Preferred: AZT + 3TC + NVP or EFV Alternative: ABC + 3TC + NVP",
            "AZT + 3TC + EFV or NVP",
            "AZT or d4T* + 3TC + NVP or EFV; or AZT + 3TC + ddI *Use only in cases of AZT toxicity when there are no other options",
            "TDF + FTC or 3TC + EFV",
            "Children < 3 years who did not receive sdNVP: AZT + 3TC + NVP Children < 3 years who received sdNVP: AZT + 3TC + LPV/r (consult HIV pediatric specialist if child is \u2264 1 month) Children > 3 years: AZT + 3TC + EFV",
            "AZT + 3TC + EFV or LPV/r",
            "Children and adolescents < 40 lbs: Preferred NRTI combination: AZT or ABC + 3TC Alternative NRTI combination: AZT + ABC or ddI Preferred third drug: NVP*; EFV\u2020 Alternative third drug: LPV/r Alternative PIs: ATV/r or FPV\u2021 or FPV/r\u00a7 or NFV Children and adolescents \u2265 40 lbs: Preferred NRTI combination: AZT or ABC or TDF + 3TC Alternative NRTI combinations: AZT + ABC or ddI Preferred third drug: NVP*; EFV\u2020 Alternative third drug: LPV/r Alternative PIs: ATV/r or FPV\u2021 or FPV/r\u00a7 or NRV * for children < 3 years \u2020 for children \u2265 3 years \u2021 for children \u2265 2 years \u00a7 for children > 6 years",
            "AZT + 3TC + NVP; or TDF + FTC + EFV",
            "Children < 3 years: AZT + 3TC + NVP Children > 3 years: AZT + 3TC + EFV",
            "d4T + 3TC + NVP",
            "Children < 12 months with infant daily NVP exposure: AZT or d4T + 3TC + LPV/r Children < 3 years or < 10 kg: AZT or d4T + 3TC + NVP Children \u2265 3 years or > 10 kg: AZT or d4T + 3TC + NVP (or EFV)",
            "AZT + 3TC + EFV; AZT + 3TC + NVP; d4T + 3TC + NVP; or d4T + 3TC + EFV",
            "Children < 3 years or weighing < 10 kg: AZT + 3TC + NVP (except when child has been exposed to NVP through PMTCT); or AZT + 3TC + EFV (for children who were exposed to NVP through PMTCT) Children \u2265 3 years and weighing 10\u201335 kg: AZT + 3TC + EFV or NVP Children weighing > 35 kg: d4T + 3TC + NVP; or AZT + 3TC + EFV",
            "d4T + 3TC + NVP For pregnant women: AZT + 3TC + NVP In patients with TB: d4T + 3TC + EFV For HIV 2: AZT + 3TC + LPV/r; or d4T + 3TC + LPV/r",
            "Children < 3 years or weighing < 10 kg: AZT + 3TC + NVP Children \u2265 3 years and weighing > 10 kg: AZT + 3TC + NVP or EFV For HIV 2: AZT + 3TC + LPV/r",
            "AZT + 3TC + EFV*; ABC + 3TC + EFV*; or TDF + 3TC + EFV* *Alternatives for third drug: ATV/r or FPV/r or LPV/r",
            "Preferred NRTI combinations: AZT + 3TC (or FTC); ddI + 3TC (FTC); or ABC + 3TC (or FTC) Alternative NRTI combinations: AZT + ddI; or ABC + AZT NNRTIs NVP (for children < 3 and as an alternative for those \u2265 3 who cannot swallow tablets); EFV (for children \u2265 3) PIs Preferred: LPV/r Alternatives: FPV/r (for children \u2265 6); ATV/r (for children \u2265 6) Postpubertal adolescents: NRTIs: TDF + 3TC PI/r: IDV/r or FVP/r or SQV/r or ATV/r",
            "Preferred: AZT + 3TC + EFV * In cases where EFV or NVP cannot be used, replace with one of the following PIs: LPV/r or SQV/r or ATV/r or FPV/r",
            "TDF + FTC + EFV or NVP",
            "Children \u2264 3 years or \u2264 10 kg: AZT + 3TC + LPV/r Children > 3 years and > 10 kg: AZT + 3TC + EFV",
            "d4T or AZT + 3TC + NVP or EFV",
            "d4T or AZT + 3TC + NVP or EFV",
            "AZT or d4T + 3TC or ddI + NVP or IDV",
            "d4T or AZT + 3TC + NVP or EFV",
            "Children < 3 years of age: AZT + 3TC + NVP Children > 3 years of age: d4T + 3TC + NVP",
            "AZT + 3TC + EFV or NVP; or d4T + 3TC + EFV Alternative: AZT + 3TC + ABC; or AZT or d4T + 3TC + LPV/r or NFV or SQV/r",
            "AZT + 3TC + EFV or NVP",
            "Children weighing < 10 kg: AZT + 3TC + NVP Children weighing > 10 kg: AZT + 3TC + EFV",
            "AZT or ddI or ABC or d4T + 3TC + EFV; AZT or d4T + 3TC + NVP; AZT + 3TC + SQV/r or LPV/r or ATV/r; or TDF + FTC + NNRTI or PI",
            "AZT + 3TC + IDV/r or EFV or NVP",
            "AZT + 3TC + NVP (< 3 years) or EFV (> 3 years) or NFV or RTV or LPV/r; AZT + ddI + NVP (< 3 years) or EFV (> 3 years) or NFV or RTV or LPV/r; or d4T + ddI + NVP (< 3 years) or EFV (> 3 years) or NFV or RTV or LPV/r",
            "d4T or AZT + 3TC + NVP or EFV; or ABC + 3TC + AZT",
            "d4T or AZT + 3TC + NVP or EFV or LPV/r",
            "Preferred drugs, first option: AZT + 3TC + NVP Preferred drugs, second option: AZT + 3TC + EFV Alternative drugs, first option: d4T + 3TC + NVP Alternative drugs, second option: d4T + 3TC + EFV",
            "d4T or AZT + 3TC + NVP or EFV",
            "First option: TDF + FTC + EFV or NVP Second option: AZT + 3TC + EFV or NVP Third option: ABC + 3TC + EFV or NVP Adolescents: Follow pediatric dosing for Tanner stages 1 and 2. Use individualized dosing for Tanner stage 3. Follow adult dosing for Tanner stages 4 and 5.",
            "Children < 3 years or < 10 kg: First option: AZT + 3TC + NVP or LPV/r Second option: ABC + 3TC + NVP or LPV/r Third option: d4T + 3TC + NVP or LPV/r Children > 3 years or > 10 kg: First option: AZT + 3TC + NVP or EFV Second option: ABC + 3TC + NVP or EFV Third option: d4T + 3TC + NVP or EFV",
            "AZT + 3TC + NVP or EFV; TDF + 3TC or FTC + EFV; or AZT + 3TC + LPV/r or ABC",
            "Children < 3 years or < 10 kg: Preferred: AZT + 3TC + NVP Alternative: d4T + 3TC + NVP Children > 3 years and > 10 kg: Preferred: AZT + 3TC + EFV Alternatives: d4T + 3TC + NVP or EFV; or ABC + 3TC + NVP or EFV",
            "Preferred: TDF + FTC + EFV or NVP Alternatives: AZT + 3TC + NVP or EFV; or ABC + 3TC + NVP or EFV",
            "Preferred: ABC + 3TC + NVP or EFV Alternatives: d4T + 3TC + NVP or EFV; or AZT + 3TC + NVP or EFV",
            "TDF + FTC + EFV or NVP; or AZT or d4T + 3TC + EFV or NVP",
            "AZT + 3TC + NVP or EFV; d4T + 3TC + NVP or EFV; or ABC + 3TC + NVP or EFV",
            "d4T + 3TC + NVP or EFV; or AZT + 3TC + NVP or EFV",
            "d4T + 3TC + NVP or EFV; or AZT + 3TC + NVP or EFV",
            "TDF + 3TC + EFV or NVP or AZT + 3TC + EFV or NVP",
            "Children not previously exposed to NVP (< 3 years or < 10 kg): Preferred: ABC + 3TC + NVP Alternative: AZT + 3TC + NVP Children not previously exposed to NVP (> 3 years or > 10 kg): Preferred: ABC + 3TC + EFV or NVP Alternative: AZT + 3TC + EFV or NVP Children previously exposed to NVP: ABC or AZT + 3TC + LPV/r",
            "AZT + 3TC + NVP or EFV; TDF + 3TC + NVP or EFV; or d4T + 3TC + NVP or EFV",
            "Children < 3 or < 10 kg: AZT or d4T + 3TC + NVP Children > 3 and > 10 kg: AZT or d4T + 3TC + EFV",
            "AZT + 3TC + NVP or EFV; TDF + 3TC + NVP or EFV; or d4T + 3TC + NVP or EFV",
            "Children < 3 kg: AZT + 3TC + NVP Children > 3 kg: d4T + 3TC + NVP",
            "d4T + 3TC + NVP; AZT + 3TC + NVP; or TDF + 3TC + EFV (for women who are pregnant or breastfeeding and those already on TB treatment)",
            "AZT + 3TC + NVP",
            "d4T + 3TC + EFV or NVP; or AZT + 3TC + EFV or NVP",
            "Children \u2264 3 years: AZT + 3TC + NVP Children \u2265 3 years: d4T + 3TC + NVP",
            "Preferred NRTI backbone: TDF + FTC Alternative NRTI backbones: ABC + 3TC; or AZT + 3TC Preferred third drug: EFV Alternative third drugs: ATV/r or LPV/r or FPV/r or SQV/r",
            "NRTI backbones: ABC + 3TC or FTC; AZT + 3TC or FTC; or ddI + FTC Third drug for children < 3 years: LPV/r Third drug for children > 3 years: LPV/r Alternative third drugs if > 6 years: ATV/r or FPV/r",
            "AZT + 3TC + NVP",
            "AZT + 3TC + EFV or NVP; TDF + 3TC or FTC + EFV or NVP",
            "Preferred: TDF + 3TC + NVP* Alternative: AZT + 3TC + NVP* * EFV should be used instead of NVP in women with CD4 > 350/mm3 or in men with CD4 > 400/mm3.",
            "Children < 24 months with known prior exposure to NVP: d4T + 3TC + LPV/r Children < 24 months without (or with unknown) prior exposure to NVP and children \u2265 24 months, but < 14 kg: d4T + 3TC/NVP Children \u2265 24 months and \u2265 14 kg and Tanner stage 1\u20133: AZT + 3TC + NVP Children \u2265 24 months and \u2265 14 kg and Tanner stage \u2265 4: TDF + 3TC + NVP",
            "AZT + 3TC + NVP or EFV; or TDF + 3TC + NVP or EFV",
            "Children < 3 years or < 10 kg: AZT + 3TC + NVP Children > 3 years and > 10 kg: AZT + 3TC + EFV Anemic children: d4T + 3TC + NVP or EFV",
            "CD4 count > 200/mm3: AZT + 3TC + EFV or NVP; or TDF + FTC or 3TC + EFV or NVP CD4 count < 200/mm3: AZT + 3TC + LPV/r; or TDF + FTC + LPV/r",
            "AZT + 3TC + NVP For patients infected with HIV-2 or HIV-1 and HIV-2: AZT + 3TC + LPV/r",
            "AZT + 3TC + EFV or NVP; or TDF + 3TC or FTC + EFV or NVP",
            "Children < 2 years with no prior NNRTI exposure: Preferred: AZT + 3TC + NVP Alternatives: ABC + 3TC + NVP; AZT + 3TC + ABC; or d4T + 3TC + NVP Children < 12 months with prior NNRTI exposure: Preferred: AZT + 3TC + LPV/r Alternatives: ABC + 3TC + LPV/r; or AZT + 3TC + ABC Children 12 months to 2 years with NNRTI exposure: Preferred: AZT + 3TC + LPV/r Alternatives: AZT + 3TC + ABC; ABC + 3TC + LPV/r; or d4T + 3TC + LPV/r Children 2\u20133 years, regardless of NNRTI exposure: Preferred: AZT + 3TC + NVP Alternatives: ABC + 3TC + NVP; AZT + 3TC + ABC; or d4T + 3TC + NVP Children > 3 years: Preferred: AZT + 3TC + EFV Alternatives: AZT + 3TC + NVP; AZT + 3TC + ABC; d4T + 3TC + NVP; or ABC + 3TC + EFV",
            "AZT + 3TC + NVP",
            "Preferred: TDF + 3TC or FTC + EFV Alternative: AZT + 3TC + EFV For pregnant women: AZT + 3TC + LPV/r; or SQV/r Alternative: AZT + 3TC + NVP",
            "Children < 3 years: AZT + 3TC or FTC + LPV/r Children \u2265 3 years: AZT + 3TC + EFV",
            "AZT + 3TC + NVP or EFV; or d4T + 3TC + NVP or EFV",
            "Children < 3 years or < 10 kg: AZT + 3TC + NVP Children > 3 years and > 10 kg: AZT + 3TC + EFV Alternative: Replace AZT with d4T in the above regimens.",
            "AZT + 3TC + EFV; AZT + 3TC + NVP; d4T + 3TC + NVP; FTC + TDF + EFV ; TDF + 3TC + EFV; or ABC + 3TC + NVP",
            "AZT + 3TC + EFV or NVP; or d4T + 3TC + EFV or NVP",
            "Preferred: 2 NRTIs + 1 NNRTI Alternative: 2 NRTIs + 1 PI or 1 NNRTI Preferred NRTI backbone: AZT + 3TC Alternative NRTI backbones: d4T + 3TC; ABC + 3TC; ABC + AZT; TDF* + 3TC; or TDF* + FTC NNRTIs: In children < 3 years: NVP In children > 3 years: EFV or NVP PIs: LPV/r or NFV * Use in adolescents.",
            "AZT + 3TC + NVP or EFV; or d4T + 3TC + NVP or EFV",
            "2 NRTIs + NNRTI or PI NRTI backbones: AZT + 3TC; ABC + 3TC; PZT + 3TC; d4T + 3TC; TDF + FTC; or ABC + ddI NNRTIs: Preferred: EFV Alternative: NVP PIs: LPV/r or IDV/r or SQV/r or FPV/r or ATV/r, ATV, or NFV",
            "d4T or TDF or AZT + 3TC + NVP or EFV",
            "d4T or AZT + 3TC + NVP",
            "The choice of first line regimen should be individualized based on potential advantages and disadvantages specific to each patient. Refer to the guidelines for further guidance.",
            "Preferred: AZT + 3TC + NVP or EFV; or d4T + 3TC + NVP or EFV Alternative: AZT + ABC + 3TC",
            "Children < 3 years or < 10 kg: AZT + 3TC + NVP; or d4T + 3TC + NVP Children > 3 years and > 10 kg: AZT + 3TC + EFV or NVP; or d4T + 3TC + EFV or NVP",
            "TDF + 3TC or FTC + EFV or NVP",
            "Children < 3 years of age or weighing < 10kg: ABC + 3TC + LPV/r Children > 3 years and weighing > 10kg: ABC + 3TC + EFV",
            "d4T or AZT + 3TC + NVP",
            "Preferred NRTI backbone: TDF + 3TC Alternative: AZT or d4 + 3TC Preferred NNRTI: EFV Alternative: NVP",
            "AZT + 3TC + EFV Alternatives to AZT: d4T or TDF Alternative to 3TC: FTC",
            "Children < 3 years: AZT + 3TC + NVP; ABC + 3TC + NVP; or d4T + 3TC + NVP Children > 3 years: AZT + 3TC + EFV or NVP; ABC + 3TC + EFV or NVP; or d4T + 3TC + NVP Children who have received NVP or 3TC as MTCT prophylaxis should be given a second-line PI-based regimen. If second-line regimen is unavailable, these children should be given an available first-line regimen.",
            "Preferred: AZT + 3TC + EFV or NVP; or TDF + 3TC or FTC + EFV or NVP Alternatives: ABC + 3TC + EFV; d4T* + 3TC + EFV or NVP; or ddI + 3TC + EFV or NVP * d4T should be replaced by another NRTI after 6\u201312 months. If patient cannot tolerate NNRTIs, replace with: Preferred: LPV/r Alternative: ATV/r or DRV/r or SQV/r",
            "Children < 3 years: Preferred: AZT + 3TC + NVP Alternative: d4T + 3TC + NVP Children > 3 years: Preferred: AZT + 3TC + EFV Alternative: AZT + 3TC + NVP; or d4T + 3TC + EFV or NVP Adolescents (weight > 40kg or Tanner stage 4): TDF + 3TC + EFV",
            "AZT + 3TC + NVP",
            "Preferred: AZT + 3TC + NVP or EFV Alternative, first option: TDF + 3TC or FTC + NVP or EFV Alternative, second option: d4T + 3TC + NVP or EFV",
            "Infants < 12 months initiating ART with previous exposure to NVP or EFV: d4T + 3TC + LPV/r Children < 5 years: d4T + 3TC + NVP or EFV Children \u2265 5 years initiating or being switched from d4T-containing regimens: AZT + 3TC + NVP or EFV",
            "Preferred: AZT + 3TC + EFV; or TDF* + FTC or 3TC + EFV Alternative: AZT + 3TC + NVP Preferred PI-based regimens: AZT + 3TC + LPV/r; or TDF* + FTC or 3TC + LPV/r Alternative PI-based regimen: AZT + 3TC + NFV * TDF and FTC require registration in Ukraine.",
            "Preferred NRTI backbones: AZT + 3TC; d4T + 3TC; AZT + ddI; or ddI + 3TC Alternative NRTI backbones: ABC + AZT; ABC + 3TC; or d4T + ddI NNRTIs: Children < 3 years: NVP Children \u2265 3 years: EFV PIs: LPV/r or NFV",
            "Preferred: EFV + TDF + FTC; or ATV/r or DRV/r or RAL + TDF + FTC",
            "Children < 3 years: Preferred: ABC or ddI or AZT + 3TC or FTC + NVP or LPV/r Alternative: AZT + ABC or ddI + NVP or LPV/r Children > 3 years: Preferred: ABC or ddI or AZT or TDF* + 3TC or FTC + EFV or LPV/r Alternative: AZT + ABC or ddI + EFV or LPV/r or NVP Children \u2265 6 years: Preferred: ABC or ddI or AZT or TDF* + 3TC or FTC + EFV or LPV/r Alternative: AZT + ABC or ddI + ATV/r or DRV/r or FPV/r + NVP * TDF for Tanner stage 4 or postpubertal adolescents only",
            "AZT + 3TC + NVP or IDV/r or SQV/r; or d4T + 3TC + EFV or NFV",
            "TDF or ABC or AZT or ddI + 3TC + EFV or NVP; or TDF or ABC or AZT or ddI + 3TC + ATV/r or FPV/r or LPV/r or SQV/r",
            "Children < 3 years: ABC or AZT or ddI + 3TC + NVP or LPV/r Children \u2265 3 years and > 10 kg: ABC or AZT or ddI + 3TC + EFV*; or TDF + 3TC\u2020 + EFV* * Can substitute LPV/r or ATV/r for EFV if > 6 years \u2020 3TC only in adolescents at Tanner stages 4 or 5",
            "Preferred: AZT + 3TC + NVP; or d4T + 3TC + NVP Alternatives: AZT + 3TC + EFV; or d4T + 3TC + EFV For patients who cannot use AZT or d4T: TDF + 3TC + NVP or EFV For patients who cannot use NVP or EFV: AZT + 3TC + TDF",
            "Preferred regimen for non-NVP-exposed children: AZT + 3TC + NVP For NVP-exposed infants < 12 months: Preferred: AZT + 3TC + LPV/r Alternatives: d4T + 3TC + LPV/r*; or ABC + 3TC + LPV/r* * If LPV/r is not available, use NVP.",
            "TDF + FTC + NVP or EFV",
            "Infants and children < 24 months with no previous NNRTI exposure: 2 NRTIs + NVP Infants and children < 24 months with previous NNRTI exposure (e.g., from PMTCT): 2 NRTIs + LPV/r Children \u2265 24 months and < 3 years: 2 NRTIs + NVP Children > 3 years: 2 NRTIs + NVP or EFV Preferential order of NRTI backbone: AZT + 3TC ABC + 3TC d4T + 3TC",
            "Preferred: TDF + 3TC + NVP Alternative: AZT + 3TC + NVP",
            "For NVP-exposed infants: Preferred: AZT + 3TC + PI (LPV/r in use now) Alternative: d4T + 3TC + PI (LPV/r in use presently) For non-NVP-exposed infants and children: Preferred: AZT + 3TC + NVP Alternative: d4T + 3TC + NVP"
        ],
        [
            "Second Line Regimen",
            "Change the combination from 2 NRTIs and 1 NNRTI to 2 NRTIs and 1 PI; or Change at least 2 of the first-line drugs TDF + 3TC + LPV/r or TDF + FTC (FDC) + LPV/r or ATV",
            "Change the combination from 2 NRTIs and 1 PI/r to 2 NRTIs and 1 NNRTI; or Change at least 2 of the first-line drugs TDF + 3TC + NVP or EFV",
            "If failed on 2 NRTIs + NNRTI switch to: 2 new NRTIs + PI/r; or 2 new NRTIs + PI/r \u00b1 NNRTI",
            "If failed on 2 NRTIs + NNRTI switch to: 2 new NRTIs + PI/r* If failed on 2 NRTIs + PI/r switch to: 2 NRTIs* + NNRTI; 2 NRTIs* + alternative PI/r*; or 2 NRTIs* + alternative PI/r* + NNRTI *based on resistance testing",
            "TDF + 3TC or FTC + LPV/r or ATV/r; or AZT + 3TC or FTC + LPV/r or ATV/r",
            "Infants and children < 24 months group 1 (not exposed to ARVs or unknown exposure): ABC or AZT + 3TC + LVP/r Infants and children < 24 months group 2 (exposed to maternal or infant NVP or other NNRTIs used for maternal treatment or PMTCT): AZT + 3TC + NVP Children > 24 months: ABC or AZT + 3TC + LVP/r",
            "d4T + 3TC + EFV or NVP",
            "3TC or AZT + ddI + IDV/r or LPV/r; or TDF + 3TC + IDV/r or LPV/r",
            "AZT + 3TC + LPV/r",
            "If failed on AZT + 3TC + NNRTI switch to: ABC + 3TC + LPV/r",
            "ddI or TDF + 3TC + NVP or ATV/r",
            "Preferred NRTI combinations: If failed on AZT or d4T + 3TC switch to: ABC + 3TC If failed on ABC + 3TC switch to: AZT + 3TC Alternative NRTI combinations: If failed on AZT or d4T + 3TC switch to: ABC + ddI If failed on ABC + 3TC switch to: AZT + ddI Preferred third drug for 2\u20136 years: LPV/r or TPV/r Preferred third drug for > 6 years: LPV/r or TPV/r or FPV/r or DRV/r or ATV/r* or T20 or RAL *for children >16 years",
            "If failed on AZT + 3TC + NVP or EFV switch to: ABC + TDF + ATV/r or LPV/r If failed on TDF + FTC + NVP or EFV switch to: ABC + AZT + ATV/r or LPV/r; or ABC + ddI + ATV/r or LPV/r",
            "ABC + ddI + LPV/r",
            "TDF + 3TC + LPV/r; or ddI + 3TC + LPV/r",
            "If failed on AZT or d4T + 3TC + NVP (or EFV) switch to: ABC + 3TC + LPV/r If failed on ABC + 3TC + NVP (or EFV) switch to: AZT + 3TC + LPV/r Children \u2265 12 years or Tanner stage > 4 who failed on AZT or d4T + 3TC + NVP switch to: TDF + 3TC (or FTC) + LPV/r If failed on PI-based regimen: Refer to specialist. After genotype analysis, it is usually recommended that patient remains on original regimen with renewed focus on adherence and dosing.",
            "______",
            "______",
            "AZT + ddI + NFV; or (d4T + ddI)* + NFV For HIV 2: d4T + ddI + LPV/r * Consider medium- and long-term side effects and decide whether to replace this combination with TDF.",
            "d4T + ddI + LPV/r or NFV",
            "Switch regimen to 3 fully active drugs. PI/r should replace the first-line NNRTI.",
            "If the first-line regimen was NNRTI-based, change to a PI-based regimen. If the first-line regimen was PI-based, change to a NNRTI-based regimen or an alternative PI reinforced with a low dose of RTV. In the case of a new NNRTI-based regimen, it is important to choose a new combination of NRTIs. A resistance test is essential in order to select a combination of NRTIs that the virus is susceptible to. In cases where there are no dual NRTI combinations that the virus is susceptible to, a regimen of 3 distinct classes of ARVs (i.e., NRTI + NNRTI + PI/r) may be indicated.",
            "If failed on AZT* or d4T + 3TC + EFV or NVP switch to: ABC + ddI + FPV\u00b1r or LPV/r If failed on AZT* or d4T + 3TC + PI switch to: ABC + ddI + EFV or NVP *AZT is preferred over d4T",
            "ddI + ABC + EFV or LPV/r",
            "ddI + ABC + LPV/r",
            "ABC or TDF + ddI + LPV/r or SQV/r or IDV/r",
            "ABC + ddI + LPV/r",
            "Refer to the guidelines for further guidance (pg. 18).",
            "ABC + ddI + LPV/r",
            "ABC + ddI + NFV",
            "ddI or TDF + ABC + LPV/r or NFV or SQV/r; TDF + 3TC (\u00b1 AZT) + LPV/r or NFV or SQV/r; or EFV or NVP \u00b1 ddI + LPV/r or NFV or SQV/r",
            "AZT + 3TC + IDV/r",
            "AZT + 3TC + LPV/r",
            "Refer to the guidelines for further guidance (pg. 42-43)",
            "d4T (for those with anemia) + 3TC + IDV/r or EFV or NVP; or AZT + ddI + IDV/r or EFV or NVP",
            "AZT or d4T + ddI or 3TC + LPV/r or NFV or RTV or NVP or IDV/r or SQV/r",
            "ABC + 3TC + LPV/r or ATV/r; AZT + ABC + LPV/r or ATV/r; TDF + 3TC + LPV/r or ATV/r; ABC + ddI + LPV/r; or EFV or NVP + LPV/r or ATV/r",
            "ABC + ddI + LPV/r or NFV",
            "ABC + ddI + LPV/r or SQV/r or NFV",
            "ABC + ddI + SQV/r or NFV",
            "If failed on first option switch to: ABC + 3TC + LPV/r or SQV/r; ABC + ddI + LPV/r or SQV/r; or AZT + ddI + LPV/r or SQV/r If failed on second option switch to: ABC + 3TC + LPV/r or SQV/r; or ABC + ddI + LPV/r or SQV/r If failed on third option switch to: ddI + 3TC + LPV/r or SQV/r; TDF + 3TC + LPV/r or SQV/r; or AZT + ddI + LPV/r or SQV/r",
            "If failed on first or third option (with EFV or NVP) switch to: ABC + ddI + LPV/r If failed on first or third option (with LPV/r) switch to: ABC + ddI + EFV If failed on second option (with EFV or NVP) switch to: AZT + ddI + LPV/r; or TDF (if > 16 years) + ABC + LPV/r If failed on second option (with LPV/r) switch to: AZT + ddI + EFV; or TDF (if > 16 years) + ABC + EFV",
            "If failed on AZT + 3TC + NVP or EFV switch to: ABC + ddI + LPV/r (or IDV/r); or TDF + FTC + LPV/r (or IDV/r) If failed on TDF + FTC + EFV switch to: ABC + ddI + LPV/r (or IDV/r) If failed on AZT + 3TC + LPV/r switch to: ABC + ddI + LPV/r (or IDV/r)",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: ddI + ABC + LPV/r or SQV/r; or ddI + AZT + LPV/r or SQV/r If failed on AZT or d4T + 3TC + ABC switch to: ddI + NVP or EFV + LPV/r or SQV/r In children < 18 months who failed on AZT or d4T + 3TC + PI/r switch to: ddI + ABC + NVP; or ddI + AZT + NVP",
            "If failed on one of the following: TDF + FTC + EFV or NVP; AZT + 3TC + NVP or EFV; d4T + 3TC + NVP or EFV, switch to: TDF + FTC + AZT + LPV/r If failed on ABC + 3TC + NVP or EFV switch to: AZT + 3TC + LPV/r If failed on any NRTI-only regimen switch to: TDF + FTC + AZT + EFV or NVP; or TDF + FTC + LPV/r If failed on any PI regimen switch to: TDF + FTC + AZT + LPV/r",
            "If failed on ABC + 3TC + NVP or EFV switch to: AZT + 3TC + LPV/r If failed on AZT or d4T + 3TC + NVP or EFV switch to: Preferred: TDF + 3TC + LPV/r Alternative: TDF + FTC + LPV/R (for children at least Tanner 3 or 35 kg) If failed on AZT + 3TC + ABC switch to: TDF + FTC + EFV or NVP; or TDF + FTC + LPV/r If failed on PI regimen: Switch NRTI backbone and continue PI",
            "AZT + 3TC + LPV/r; or TDF + FTC + LPV/r",
            "If failed on a regimen containing AZT or d4T switch to: ddI + ABC + LPV/r or SQV/r or NFV If failed on a regimen containing ABC switch to: ddI + AZT + LPV/r or SQV/r or NFV If failed on regimen containing 3 NRTIs switch to: ddI + EFV or NVP + LPV/r or SQV/r or NFV",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: ddI + ABC + LPV/r or SQV/r or NFV If failed on ABC or 3TC + NVP or EFV switch to: ddI + AZT + LPV/r or SQV/r or NFV If failed on AZT or d4T + 3TC + ABC switch to: ddI + EFV or NVP + LPV/r or SQV/r or NFV",
            "ABC + ddI + LPV/r or SQV/r or NFV",
            "AZT + 3TC + LPV/r or ATV/r*; or TDF + 3TC + LPV/r * The national therapeutic committee should be consulted for patients who initiated a PI-based regimen as their first-line regimen and subsequently fail treatment.",
            "Children not previously exposed to NVP (if failed on a regimen containing ABC) switch to: AZT + 3TC + LVP/r Children not previously exposed to NVP (if failed on a regimen containing AZT) switch to: ABC + 3TC + LVP/r Children previously exposed to NVP: Discuss with national ARV therapeutics TWG.",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: TDF + 3TC \u00b1 AZT + LPV/r or ATV/r If failed on TDF + 3TC + NVP or EFV switch to: ddI + 3TC \u00b1 AZT + LPV/r or ATV/r; ddI + ABC + LPV/r or ATV/r; or AZT + 3TC + LPV/r or ATV/r",
            "ddI + ABC + LPV/r or ATV/r",
            "TDF or AZT + 3TC + LPV/r or ATV/r or NFV; or ABC + ddI + LPV/r or ATV/r or NFV",
            "ABC + ddI + LPV/r or NFV",
            "TDF + 3TC + LPV/r; or AZT + 3TC + LPV/r",
            "ABC + 3TC + LPV/r",
            "ABC + ddI + LPV/r or IDV/r",
            "If failed on d4T or AZT + 3TC + NVP or EFV switch to: Preferred: TDF or ABC + ddI + LPV/r or SQV/r Alternative: ABC + ddI + NFV",
            "NRTI backbone (if failed on TDF + FTC) switch to: TDF + AZT NRTI backbone (if failed on ABC + 3TC or FTC) switch to: TDF + AZT NRTI backbone (if failed on AZT + 3TC) switch to: TDF + AZT Third drug (if failed on EFV or NVP or ATV/r) switch to: LPV/r Third drug (if failed on LPV/r): Consult the institutional committee for review",
            "2 new NRTIs If failed on EFV or NVP, switch to: ETV If failed on a PI switch to: NNRTI",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: TDF + (AZT + 3TC) + LPV/r; TDF + 3TC + LPV/r; ABC + ddI + LPV/r; or TDF + (AZT + 3TC) + SQV/r",
            "If failed on d4T or AZT switch to: TDF + 3TC or FTC + ATV/r or LPV/r If failed on TDF switch to: AZT + 3TC + ATV/r or LPV/r",
            "AZT + TDF + 3TC + LPV/r Note that ABC and ddI can be considered as backup options in case of AZT or TDF toxicity or contraindication.",
            "Children in Tanner stages 1\u20133 on NNRTI-based first-line regimen switch to: ABC + AZT + 3TC + LPV/r Children in Tanner stages 1\u20133 on PI-based first-line regimen switch to: ABC + AZT + 3TC + NVP or EFV Children in Tanner stages 4 or 5 on NNRTI-based first-line regimen switch to: TDF* + AZT + 3TC + LPV/r Children in Tanner stages 4 or 5 on PI-based first-line regimen switch to: TDF* + AZT + 3TC + NVP or EFV * If the first-line regimen included TDF, seek advice of an HIV specialist.",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: TDF + 3TC + LPV/r If failed on TDF + 3TC + NVP or EFV switch to: ddI + ABC + LPV/r",
            "______",
            "CD4 count > 200/mm3 switch to: ABC or ddI + 3TC or FTC + LPV/r or ATV/r or SQV/r or DRV/r CD4 count < 200/mm3 switch to: ABC or ddI + 3TC + EFV or NVP; or ABC or ddI + 3TC + ATV/r or SQV/r or DRV/r",
            "ABC + ddI + LVP/r",
            "If failed on d4T or AZT switch to: TDF + 3TC or FTC + ATV/r or LPV/r If failed on TDF switch to: AZT + 3TC + ATV/r or LPV/r",
            "If failed on AZT + 3TC + NVP switch to: ABC + 3TC + LVP/r; or d4T + 3TC + LPV/r If failed on ABC + 3TC + NVP switch to: AZT + 3TC + LVP/r; d4T + 3TC + LPV/r; or ddI + 3TC + LPV/r If failed on AZT + 3TC + ABC switch to: ddI + 3TC + NVP; TDF + 3TC + EFV; or ddI + 3TC + LPV/r If failed on d4T + 3TC + NVP switch to: ABC + 3TC + LVP/r; ddI + 3TC + LPV/r; or AZT + 3TC + ABC If failed on AZT + 3TC + LPV/r switch to: ABC + 3TC + ddI; or ddI + ABC + NVP or EFV If failed on ABC + 3TC + LPV/r switch to: AZT + 3TC + ddI; or AZT + 3TC + NVP or EFV If failed on AZT or d4T + 3TC + EFV switch to: ABC + 3TC + LPV/r If failed on TDF + 3TC or FTC + EFV or NVP switch to: AZT + 3TC + LVP/r; d4T + 3TC + LPV/r; ABC + 3TC + AZT; or ABC + 3TC + d4T",
            "TDF or ABC + ddi + NFV",
            "If failed on TDF + 3TC or FTC + EFV switch to: AZT + ABC or ddI + LPV/r or SQV/r or ATV/r If failed on AZT + 3TC + EFV switch to: TDF + ABC + LPV/r or SQV/r or ATV/r If failed on a PI-based first-line regimen, refer to an infectious disease specialist.",
            "Children < 3 years switch to: AZT + 3TC or FTC + NVP Children \u2265 3 years switch to: AZT + 3TC + LPV/r",
            "If failed on AZT + 3TC + NVP or EFV switch to: TDF or ddI + ABC + LPV/r or SQV/r If failed on d4T + 3TC + NVP switch to: TDF + ABC + LPV/r If failed on d4T + 3TC + EFV switch to: ddI + ABC + SQV/r If failed on d4T + 3TC + EFV switch to: TDF + ABC + SQV/r",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: ddI + ABC + LPV/r or SQV/r If failed on AZT or d4T + 3TC + ABC switch to: ddI + EFV or NVP + LPV/r",
            "AZT + 3TC + IDV/r; d4T + 3TC + IDV/r; AZT + 3TC + LPV/r; FTC + LPV/r; d4T + 3TC + LPV/r; or ABC + 3TC + LPV/r",
            "2 new NRTIs + LPV/r or ATV/r or SQV/r",
            "If failed on regimen of 2 NRTIs + 1 NNRTI switch to: 2 new NRTIs + PI/r; or 1 new NRTI + 3TC + PI/r If failed on regimen of 2 NRTIs + PI/r switch to: 2 new NRTIs + 1 new PI/r; 1 new NRTI + NNRTI + PI/r; or 2 new NRTIs + NNRTI (if not previously on an NNRTI) If failed on AZT + 3TC + NVP or EFV switch to: Children < 6 years: ABC + 3TC + LPV/r Children > 6 years: TDF + 3TC + LPV/r",
            "AZT or TDF + 3TC + LPV/r",
            "Some of the ARVs used in second-line regimens are ATV, ATV/r, DRV, and TPV. Refer to page 38 of the guidelines for further information.",
            "ABC or AZT or d4T + 3TC + LPV/r or EFV",
            "ddI + ABC + LPV/r",
            "The choice of second line regimen should be individualized based on potential advantages and disadvantages specific to each patient. Refer to the guidelines for further guidance.",
            "2 new NRTIs + PI/r Preferred: AZT + 3TC + IDV/r Alternative: AZT + 3TC + LPV/r",
            "If failed on AZT + 3TC backbone switch to: d4t + ddI If failed on d4T + 3TC backbone switch to: AZT + ddI If failed on EFV or NVP switch to: Switch third drug to LPV/r If failed on LPV/r switch to: Switch third drug to EFV or NVP",
            "AZT + 3TC + LPV/r",
            "______",
            "ABC + ddI + LPV/r",
            "ABC + ddI + LPV/r* * Use SQV/r or ATV/r or IDV/r in patients who cannot tolerate LPV/r.",
            "If failed on AZT or d4t switch to: TDF + 3TC or FTC + LPV/r or ATV/r If initiated on TDF due to intolerance to AZT or d4T switch to: ABC + ddI + LPV/r or ATV/r",
            "ddI + ABC + LPV/r or NFV",
            "If first regimen was NNRTI-based switch to: PI/r + 2 active NRTIs indicated by genotypic testing If first regimen was PI/r-based switch to: Active PI/r + 2 active NRTIs indicated by genotypic testing; Active PI/r + 1 NNRTI \u00b1 1 NRTI indicated by genotypic testing; or NNRTI + 2 active NRTIs indicated by genotypic testing",
            "2 NRTIs + PI/r Select NRTIs guided by genotype of RT gene. Refer to Figure 1 on page 510 of the guidelines for specific second-line regimens recommended for different scenarios.",
            "If failed on AZT or ABC or d4T switch to: TDF + 3TC + LPV/r or ATV/r If failed on TDF switch to: AZT + 3TC + LPV/r or ATV/r; or ABC + 3TC + LPV/r or ATV/r",
            "If failed on AZT + 3TC + NVP or EFV switch to: ABC + ddI + LPV/r; or TDF + 3TC or FTC + LPV/r If failed on TDF + 3TC or FTC + NVP or EFV switch to: AZT + ddI + LPV/r; ABC + ddI + LPV/r; or AZT + 3TC + LPV/r If failed on d4T + 3TC + NVP or EFV switch to: ABC + ddI + LPV/r; or TDF + 3TC or FTC + LPV/r",
            "If failed on d4T + 3TC + NVP or EFV switch to: ABC + ddI + LPV/r or ATV/r; TDF + 3TC or FTC + LPV/r; or AZT + 3TC + ATV/r If failed on AZT + 3TC + NVP or EFV switch to: ABC + ddI + LPV/r or ATV/r; or TDF + 3TC or FTC + LPV/r If failed on d4T + 3TC + LPV/r switch to: ABC + ddI + NVP or EFV",
            "If failed on AZT + 3TC + EFV or NVP switch to: ddI + ABC or TDF or AZT or 3TC + LPV/r; or TDF + ABC or (3TC \u00b1 AZT) or ddI + LPV/r If failed on TDF + FTC or 3TC + EFV or NVP switch to: ddI + ABC or AZT or (3TC \u00b1 AZT) + LPV/r If failed on AZT + 3TC + LPV/r switch to: ddI + AZT or ABC + LPV/r; or TDF + ABC or AZT or (3TC \u00b1 AZT) + LPV/r If failed on TDF + FTC + LPV/r switch to: ddI + ABC or AZT + LPV/r If failed on AZT + 3TC + NFV switch to: AZT + ddI + LPV/r",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: ddI + ABC + LPV/r or SQV/r or NFV If failed on ABC + 3TC + NVP or EFV switch to: ddI + AZT + LPV/r or SQV/r or NFV If failed on AZT or d4T + 3TC + LPV/r or NFV switch to: ddI + ABC + LPV/r or EFV or NVP If failed on ABC + 3TC + LPV/r or NFV switch to: ddI + AZT + LPV/r or EFV or NVP If failed on AZT or d4T + 3TC + ABC switch to: ddI + EFV or NVP + LPV/r or SQV/r or NFV",
            "Patient\u2019s treatment history and former and current resistance test results should be used to identify at least 2 (preferably 3) fully active agents to combine with an optimized background ARV regimen. Refer to the guidelines for further guidance (pg. H-1).",
            "If failed on 2 NRTIs + NNRTI switch to: 2 NRTIs + PI If failed on 2 NRTIs + PI switch to: 2 NRTIs + NNRTI; 2 NRTIs + PI/r; or NRTI(s) + NNRTI + PI/r If failed on 3 NRTIs switch to: 2 NRTIs + NNRTI or PI; or NRTI(s) + NNRTI + PI",
            "2 NRTIs + EFV or NFV or IDV/r or SQV/r; 2 NRTIs + 1 NNRTI + SQV/r or LPV/r; or 1 NRTI + 1 NNRTI + SQV/r",
            "If failed on TDF + 3TC backbone switch to: AZT + ABC; ddI + AZT; or ddI + ABC If failed on ABC + 3TC backbone switch to: TDF + AZT; or AZT + ddI If failed on AZT + 3TC backbone switch to: ABC + ddI; or TDF + ABC If failed on ddI + 3TC backbone switch to: TDF + AZT; or TDF + ABC If failed on AZT + ddI backbone switch to: TDF + 3TC; or ABC + 3TC If failed on d4T + ddI backbone switch to: TDF + 3TC; ABC + 3TC; or TDF + AZT If failed on AZT + ABC + 3TC switch to: PI/r + EFV + TDF or ddI If failed on d4T + 3TC backbone switch to: TDF + ABC; or ABC + ddI If failed on d4T or AZT + ABC backbone switch to: TDF + 3TC If failed on NNRTI-based regimen, switch to PI/r switch to: ATV/r or FPV/r or LPV/r or SQV/r If failed on PI/r-based regimen switch to NNRTI: EFV or NVP",
            "If failed on 2 NRTIs + NNRTI switch to: 2 NRTIs + PI/r If failed on 2 NRTIs + PI/r switch to: 2 NRTIs + PI/r with a higher genetic barrier; or NRTI + NNRTI + PI/r with a higher genetic barrier",
            "If failed on d4T or AZT + 3TC + NVP or EFV switch to: TDF + 3TC (\u00b1 AZT) + LPV/r*; or ddI + ABC + LPV/r* If failed on TDF + 3TC + NVP or EFV switch to: ddI + ABC + LPV/r*; or AZT + 3TC + LPV/r* If failed on AZT or d4T + 3TC + TDF or ABC switch to: EFV or NVP + ddI + LPV/r* * ATV/r can be used as an alternative for LPV/r.",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: ddI + ABC + LPV/r* If failed on AZT or d4T + 3TC + ABC switch to: ddI + EFV + LPV/r*; or ddI + NVP + LPV/r* If failed on ABC + 3TC + NVP or EFV switch to: AZT + 3TC (\u00b1 ddI) + LPV/r*; or d4T + 3TC + LPV/r* * ATV/r can be used as an alternative for LPV/r.",
            "AZT or d4T + 3TC or TDF/FTC + LPV/r",
            "If failed on AZT or d4T + 3TC + NVP or EFV switch to: ABC + 3TC + LPV/r In children > 12 years switch to: TDF + FTC or 3TC + LPV/r If failed on ABC + 3TC + NVP or EFV switch to: AZT + 3TC + LPV/r If failed on AZT or d4T + 3TC + LPV/r switch to: ABC + 3TC + NVP or EFV If failed on ABC + 3TC + LPV/r switch to: AZT + 3TC + NVP or EFV",
            "Preferred: AZT + 3TC* + LPV/r If failed on regimen containing AZT or d4T switch to: TDF + 3TC* + LPV/r Alternative: ABC + ddI + LPV/r\u2020 * 3TC may be replaced with FTC \u2020 ATV/r is an alternative PI",
            "If failed on regimen with PI switch to: Preferred: ABC + 3TC + NVP Alternative: ABC + ddI + NVP If failed on regimen with NVP switch to: Preferred: ABC + 3TC + PI (LPV/r in use presently) Alternative: ABC + ddI + PI (LPV/r in use presently)"
        ],
        [
            "Third Line Regimen",
            "Substitute 1 of the following drugs for each of at least 2 of the second-line drugs: DRV or ETV or RAL or ddI",
            "______",
            "If failed on 2 NRTIs + PI/r or 1\u20132 NRTIs + PI/r + NNRTI switch to: 1\u20132 NRTIs + new PI/r \u00b1 NNRTI",
            "Refer to pg. 118 of the guidelines.",
            "______",
            "______",
            "______",
            "______",
            "Resistance specialist required",
            "______",
            "______",
            "In cases of resistance in 3 drug classes (e.g., NRTI, NNRTI, and PI), the decision must be individualized, based on genotypic testing and recent patient medical history. If new classes of medicines are not available, assess off-label use of available drugs or inclusion in a clinical trial.",
            "Any change to third-line treatment should be decided by an expert panel. Choice of drugs would include a new NNRTI, an integrase inhibitor and a new PI/r (e.g., ETV, RAL, or DRV/r).",
            "Any change to third-line treatment should be decided by an expert panel. Choice of drugs would include a new NNRTI, an integrase inhibitor and a new PI/r (e.g., ETV, RAL, or DRV/r).",
            "_______",
            "______",
            "______",
            "______",
            "______",
            "Genotyping",
            "______",
            "______",
            "Perform genotypic testing on patients with a second or third treatment failure. Always confirm virological failure and a viral load > 1,000 copies/mL before ordering a genotypic test.",
            "______",
            "______",
            "Refer to specialized hospital",
            "Refer to specialized hospital",
            "______",
            "______",
            "______",
            "______",
            "Use of four or more ARVs. See guidelines for further guidance (pg. 64-67).",
            "______",
            "______",
            "______",
            "Patients must visit a specialized health center.",
            "______",
            "______",
            "______",
            "______",
            "Genotypic testing is required. Consult the recommendations of the Committee on Drug Resistance (Comit\u00e9 de Farmacorresistencia). Patients should continue on second-line treatment until third-line treatment is available. Patients should be referred to one of the following clinics for treatment before returning to their home clinic: Cl\u00ednica de Enfermedades Infecciosas, Hospital Roosevelt Cl\u00ednica Familiar Lu\u00eds \u00c1ngel Garc\u00eda\u2014ASI Hospital General San Juan de Dios",
            "Genotypic testing is required. Consult the recommendations of the National Committee on Drug Resistance (Comit\u00e9 de Farmacorresistencia).",
            "Discuss with multidisciplinary team and refer to specialist center. Review treatment history and send for genotypic testing. 2 NRTI + DRV/r + RAL or ETV",
            "______",
            "It is recommended that clinicians continue the use of second-line regimens while contacting an HIV treatment specialist or the NCTC.",
            "It is recommended that clinicians continue the use of second-line regimens while contacting an HIV treatment specialist or the NCTC.",
            "______",
            "Third-line ART can sometimes be provided in centers where viral load, genotype, and phenotype testing are available. Regimens consisting of 5 or more drugs (including 2 PIs), the use of T20, and remaining on the current regimen until other ARVs are available are some of approaches that have been used. In these cases, management is difficult and requires a doctor from a tertiary hospital with sufficient experience in pediatric HIV treatment.",
            "______",
            "______",
            "Maintain the patient on the failing regimen until a full third-line regimen is available as recommended by the national TWG. Third-line regimens should contain at least 2 fully active drugs for durable, potent virologic suppression. Third-line regimen choice must be guided by resistance testing. Possible third-line agents: DRV, RAL, 3TC, and TDF (recycling drugs); ETV.",
            "Children experiencing treatment failure on second-line therapy should be managed in consultation with senior clinicians experienced in HIV treatment. A framework is being developed by NASCOP to facilitate effective management of patients failing second-line therapy.",
            "______",
            "______",
            "_______",
            "______",
            "______",
            "______",
            "______",
            "______",
            "Patient should be sent to referral center for expert review. Resistance testing (genotypic or phenotypic) is necessary in addition to thorough review of patient\u2019s treatment history. Use at least 2, preferably 3, active ARVs. The following drugs can be used in third-line regimens and are available in Mexico. The institutional committee must authorize the prescription of these drugs: PIs: DRV, TPV NNRTI: ETV Integrase inhibitor: RAL CCR5 inhibitor: MVC Fusion inhibitor: T20",
            "The following drugs can be used in third-line regimens and are available in Mexico. The institutional committee must authorize the prescription of these drugs: PIs: DRV, TPV NNRTI: ETV Integrase inhibitor: RAL CCR5 inhibitor: MVC Fusion inhibitor: T20",
            "______",
            "Refer to page 29 of guidelines.",
            "Third-line regimens are complicated and should only be implemented following the recommendation and close supervision of an HIV specialist.",
            "An HIV specialist can give approval for resistance testing for a child failing a second-line regimen and should be consulted for further management of the child.",
            "______",
            "______",
            "______",
            "Available alternative ARVs: ATV or SQV or DRV or RAL or ETV",
            "Genotype or phenotype resistance testing is not readily available. Conduct a comprehensive evaluation to ascertain the cause of failure. Recommended salvage therapy: DRV/r + RAL with an optimized background of NRTIs including 3TC or FTC. If salvage regimen is unavailable, continue patient on optimized second-line regimen",
            "Children with such needs should be referred to higher levels of care or ART specialists if necessary. When salvage treatment is unavailable, a failing second-line regimen may be continued because there is evidence of some benefit despite the emergence of resistance mutations.",
            "______",
            "Virologic failure does not always warrant a change in triple therapy. If a regimen change is necessary, it should be done as soon as possible to avoid greater resistance. Patient adherence must be evaluated. The new regimen should have at least 2 (preferably 3) different active drugs such as RAL or MVC or DRV or EFV.",
            "______",
            "______",
            "______",
            "If not used in first- or second-line regimen switch to: AZT + 3TC + ABC; AZT + 3TC + TDF; or AZT + 3TC + ddI",
            "______",
            "The following drugs may be indicated after consultation with the committee of experts: ATV or SQV or DRV or MVC or AMP or FPV",
            "______",
            "______",
            "______",
            "______",
            "______",
            "______",
            "______",
            "______",
            "______",
            "______",
            "______",
            "ART regimen should be continued until patient is no longer receiving clinical benefits from treatment. If the patient is at WHO clinical stage 4 while on second-line regimen, expert opinion should be sought regarding stopping ART and instituting palliative care.",
            "______",
            "At least 2 new active ARVs, such as DRV/r or ETV or RAL Refer to expert consultation or appropriate clinical trial in cases where these drugs are not available. While waiting for new drugs, a holding regimen consisting of 3TC and other NRTIs may be considered.",
            "To design a salvage regimen, use at least 2 active drugs plus a recycled NRTI. Access to new drugs such as DRV, MVC, ETV, and RAL may be needed. Expert consultation is recommended. Refer to page 511 of the guidelines for further information.",
            "______",
            "______",
            "______",
            "Considerations for salvage regimens: Addition of 2 active drugs such as T20 and TPV or another new PI A combination of 2 PIs (except for TPV, which is not recommended in combination with other PIs)",
            "This requires consultation with an experienced professional. Strategic approaches include: T20 Reuse of ARVs Structured treatment interruption The continuation of current therapy until appropriate drugs are available",
            "Refer to pg. H-1 of the guidelines.",
            "Refer to guidelines for further information (pg. 130\u2013136).",
            "______",
            "Available third-line drugs: DRV, ETV, RAL, T20 Include 2 active ARVs in a 3-drug regimen.",
            "Refer to CONARESAR for further guidance. For more information, see pg. 37 of the guidelines.",
            "______",
            "______",
            "______",
            "Considerations: For older children with more therapeutic options available, it may be possible to construct third-line regimens with novel drugs used for adults (i.e., DRV and RAL) Children on failing second-line regimens with no new ARV options should continue with a tolerated regimen When stopping ART, management of OIs, symptoms and pain must continue For further information on the failure of second-line regimens, refer to page 73 of the guidelines.",
            "______",
            "______"
        ]
    ],
    "pageTitle": "Summary table of HIV treatment regimens | AIDSTAR-One",
    "title": "",
    "url": "http://aidstar-one.com/focus_areas/treatment/resources/regimes_summary?Ghana",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 0,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990611.52/warc/CC-MAIN-20150728002310-00072-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 5622047,
    "recordOffset": 5582807,
    "tableOrientation": "HORIZONTAL",
    "lastModified": "Mon, 27 Jul 2015 18:45:25 GMT",
    "textBeforeTable": "Summary table of HIV treatment regimens How we can help From short-term technical assistance to long-term program implementation support and more, AIDSTAR-One provides rapid, evidence-based services to PEPFAR country teams in generalized, mixed and concentrated HIV epidemic settings. \u00a0 What can AIDSTAR-One do for you? Subscribe now Sign up to receive current HIV technical resources delivered to your inbox. Customize your updates based on your areas of interest. \u00a0 Subscribe to AIDSTAR-One! National HIV Treatment Regimen Summaries National HIV Treatment Guidelines",
    "textAfterTable": "Refine by region: Refine by target population: Refine by country: Africa (30) Asia (9) Latin America & Caribbean (20) North America (1) Oceania (2) Russia & Eastern Europe(2) Infants and children (#) Adults and adolescents (#) Pregnant women (#) <Any> Algeria Argentina Bangladesh Bhutan Bolivia Botswana Brazil Burundi Cambodia Cameroon Cape Verde Chile Colombia Comoros C\u00f4te d Ivoire Cuba Democratic Republic of Congo Djibouti Dominican Republic Ecuador El Salvador Ethiopia Ghana Guatemala Guinea Guyana Haiti India Kenya Lesotho Liberia Malawi Mauritania Mexico Mozambique Myanmar Namibia Nepal Nicaragua Niger Nigeria Pakistan Panama Papua New Guinea Paraguay",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}